Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase I/II trial is to see if combining erlotinib with bevacizumab works
better in treating patients who have recurrent or metastatic head and neck cancer. Erlotinib
may stop the growth of tumor cells by blocking the enzymes needed for tumor cell growth.
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or deliver cancer-killing substances to them. Combining erlotinib with bevacizumab may
kill more tumor cells.